These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 34550621)

  • 21. Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers.
    Pachi I; Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Stamelou M; Trapali XG; Papageorgiou SG; Stefanis L
    Parkinsonism Relat Disord; 2021 Oct; 91():1-8. PubMed ID: 34425330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
    da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
    J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
    Ruz C; Alcantud JL; Vives F; Arrebola F; Hardy J; Lewis PA; Manzoni C; Duran R
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
    Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
    J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease.
    Sosero YL; Yu E; Krohn L; Rudakou U; Mufti K; Ruskey JA; Asayesh F; Laurent SB; Spiegelman D; Fahn S; Waters C; Sardi SP; Bandres-Ciga S; Alcalay RN; Gan-Or Z; Senkevich K
    Neurobiol Aging; 2021 Jul; 103():142.e1-142.e5. PubMed ID: 33781610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variants in PSMB9 and FGR differentially affect Parkinson's disease risk in GBA and LRRK2 mutation carriers.
    Shani S; Goldstein O; Gana-Weisz M; Bar-Shira A; Thaler A; Gurevich T; Mirelman A; Giladi N; Alcalay RN; Orr-Urtreger A
    Parkinsonism Relat Disord; 2023 Jun; 111():105398. PubMed ID: 37116292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in the Parkinson's disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor.
    Clark LN; Kisselev S; Park N; Ross B; Verbitsky M; Rios E; Alcalay RN; Lee JH; Louis ED
    Parkinsonism Relat Disord; 2010 Feb; 16(2):132-5. PubMed ID: 19527940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients.
    Alcalay RN; Wolf P; Chiang MSR; Helesicova K; Zhang XK; Merchant K; Hutten SJ; Scherzer C; Caspell-Garcia C; Blauwendraat C; Foroud T; Nudelman K; Gan-Or Z; Simuni T; Chahine LM; Levy O; Zheng D; Li G; Sardi SP;
    Ann Clin Transl Neurol; 2020 Oct; 7(10):1816-1830. PubMed ID: 32888397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews.
    Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R
    Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis.
    Huang J; Cheng Y; Li C; Shang H
    Transl Neurodegener; 2022 Apr; 11(1):21. PubMed ID: 35395825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
    von Linstow CU; Gan-Or Z; Brundin P
    Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
    Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS
    Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.
    Gan-Or Z; Giladi N; Rozovski U; Shifrin C; Rosner S; Gurevich T; Bar-Shira A; Orr-Urtreger A
    Neurology; 2008 Jun; 70(24):2277-83. PubMed ID: 18434642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Plasma Exosomes in Inherited Forms of Parkinson's Disease].
    Kulabukhova DG; Garaeva LA; Emelyanov AK; Senkevich KA; Gracheva EV; Miliukhina IV; Varfolomeeva EY; Timofeeva AA; Schwartsman AL; Shtam TA; Pchelina SN
    Mol Biol (Mosk); 2021; 55(2):338-345. PubMed ID: 33871446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occupational Pesticide Exposure in Parkinson's Disease Related to GBA and LRRK2 Variants.
    Brown EG; Goldman SM; Coffey CS; Siderowf A; Simuni T; Meng C; Brumm MC; Caspell-Garcia C; Marek K; Tanner CM;
    J Parkinsons Dis; 2024; 14(4):737-746. PubMed ID: 38820021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
    Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
    J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers.
    Zhang D; Shi Y; Yao J; Zhou L; Wei H; Liu J; Tong Q; Ma L; He H; Wu T
    Mov Disord; 2023 May; 38(5):764-773. PubMed ID: 36797645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
    den Heijer JM; Cullen VC; Pereira DR; Yavuz Y; de Kam ML; Grievink HW; Moerland M; Leymarie N; Khatri K; Sollomoni I; Spitalny L; Dungeon L; Hilt DC; Justman C; Lansbury P; Groeneveld GJ
    Mov Disord; 2023 May; 38(5):783-795. PubMed ID: 36916660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
    Noyce AJ; R'Bibo L; Peress L; Bestwick JP; Adams-Carr KL; Mencacci NE; Hawkes CH; Masters JM; Wood N; Hardy J; Giovannoni G; Lees AJ; Schrag A
    Mov Disord; 2017 Feb; 32(2):219-226. PubMed ID: 28090684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.